Natera Inc. Terminates NIPT Distribution Agreement with Bioreference Laboratories
January 10, 2017 at 08:00 am
Share
Natera, Inc. announced the termination of a distribution agreement with Bioreference Laboratories. With the ending of the distribution agreement, Natera intends to promote Panorama directly to clinicians, who previously ordered this test through Bio-Reference. Natera also plans to promote its Horizon carrier screen test to these clinicians, which it had not done previously.
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of womenâs health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Companyâs algorithms and bioinformatics in order to validate and launch tests based on the Companyâs technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
NATERA, INC. 
